Trial · NCT06511765
Anesthetic Block of the Erector Muscles of the Lumbar Spine to Relieve Acute Lumbar Pain: Pilot Study
NCT06511765, Phase 3, Recruiting, Elsan
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Anesthetic Block of the Erector Muscles of the Lumbar Spine to Relieve Acute Lumbar Pain: Pilot Study. Trials, record NCT06511765. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06511765
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Anesthetic Block of the Erector Muscles of the Lumbar Spine to Relieve Acute Lumbar Pain: Pilot Study
- NCT number
- NCT06511765
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Elsan
- Conditions
- Lumbago
- Interventions
- Ropivacaine and dexamethasone injection solution, Sodium Chloride 0.9% Injection Solution
- First posted
- 2024-07-22
- Last updated
- 2026-06-10
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Lumbar pain in activity | At Hour 0-Hour1-Hour4-Hour8-Hour12 and Day 1-Day2-Day3-Day4. (Hour 0=injection time, Day 1=One day after injection time) | Area under the curve of lumbar pain in activity measured by the patient on a numeric scale (from 0=no pain, and 10=unbearable pain) |
| Secondary | Consumption of concomitant lumbago treatments | From Day 0 (day of injection) to Day 4 | Recording of analgesics and NSAIDs, physiotherapy, manipulations, open surgery, etc |
| Secondary | Lumbar pain at rest | Day 4 | Lumbar pain measured by the patient on a numeric scale |
| Secondary | Lumbar pain in activity | Day 4 | Lumbar pain measured by the patient on a numeric scale |
| Secondary | Lumbar pain at rest | At Hour 0-Hour1-Hour4-Hour8-Hour12 and Day 1-Day 2-Day 3-Day 4-Day 7-Day 14-Day 21-Day 28 | Area under the curve of lumbar pain at rest measured by the patient on a numeric scale |
| Secondary | Lumbar Pain < 3 | Day 4 | Percentage of patients with pain \< 3 (measured by the patient on a numeric scale, at rest) |
| Secondary | Algofunctional index | Day 0, Day 4 and Day 28 | Oswestry questionnaire: comprises 10 questions on pain, personal care, load-bearing, walking, sitting, standing, sleep, sex life, social life and travel. Each question offers 6 answers, with a score from 0 to 6, which the patient must choose; a score of 0 corresponds to normal function, and a score of 6 to severely impaired function. The score obtained is multiplied by 2 to obtain a percentage of disability, with 0% for no disability, and 100% for the greatest disability. |
| Secondary | Duration of the interruption of current activities | 28 days | Number of days without current activities |
| Secondary | Duration of the interruption of work | 28 days | Number of days of sick leave |
| Secondary | Complications | 28 days | Complications will focus on the following adverse events: 1. injection-site hematoma, nerve damage, limb pain, convulsions, respiratory discomfort, bradycardia, severe vagal malaise 2. fall, iatrogenic infection 3. new lumbago, sciatica or complicated crural neuralgia (neurological deficit, cauda equina syndrome) 4. allergy, digestive complication, renal complication 5. other to be specified |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06511765
GET https://conductscience.org/api/trials/v1/NCT06511765/registered